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Introduction
Colorectal carcinoma is the second most common cancer
in the UK after lung cancer and accounts for approximately
20,000 patient deaths per year.1 Approximately 50% of
patients who undergo supposedly curative resection of
colorectal cancer die from metastatic disease within 5 years.
The prognosis for these patients mainly depends on tumour
stage. Staging of colorectal cancer has remained unchanged
since Dukes’ classification of rectal cancer. Lymph node me-
tastasis in colorectal cancer remains the most important prog-
nostic factor in non-metastatic cancer, with approximately
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60% to 70% of lymph node-positive patients dying within
5 years of surgery. Other factors such as age, gender and
histopathological variables can influence survival. Almost 30%
of node-negative patients relapse and die of disseminated
disease. Recently, abnormalities in hepatic haemodynamics
have been shown to occur in patients and animals with hepatic
metastases, notably decreased blood flow through the portal
vein caused by splanchnic vasoconstriction.2 Furthermore,
such abnormal hepatic haemodynamics may be useful in
predicting poor outcome in patients with colorectal cancer.3
The blood vessels supplying colorectal hepatic metastases
are quite different from the normal hepatic vessels and lack
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AIM: Prognostic indicators from clinical, laboratory and pathological data of patients with colorectal cancer are
essential to identify high-risk groups in whom adjuvant therapy could be beneficial. Endothelin-1 (ET-1), a
growth factor, has been associated with the development and spread of solid tumours. This prospective study was
performed to determine whether preoperative plasma big ET-1 concentrations might be useful as a prognostic
indicator in patients with colorectal carcinoma.
METHODS: Overall, 65 consecutive patients with colorectal cancer confirmed by biopsy were included prospec-
tively in this study from 1998 to 2001. Plasma samples from a peripheral vein were obtained prior to surgery.
Univariate analysis of survival used age (less than or more than 70 years), gender, Dukes’ stage (A/B vs C), tumour
size (less than or more than 50 mm), vascular invasion, and plasma big ET-1 concentrations, and significant
factors were then analysed using a Cox regression model.
RESULTS: Three variables, age, Dukes’ tumour stage and plasma big ET-1 concentration, had prognostic
significance (p < 0.05). Factors associated with a poorer prognosis were age more than 70 years (p = 0.02), Dukes’
C (p = 0.04) and plasma big ET-1 concentration more than 4.2 pg/mL (p = 0.02). The Cox regression model
identified the same three variables as having independent prognostic value for overall survival.
CONCLUSION: Preoperative plasma big ET-1 concentrations may be useful in predicting overall survival in
patients with colorectal cancer. Plasma big ET-1 concentrations may be useful in the selection of high-risk, lymph
node-negative patients with colorectal cancer for adjuvant therapy. [Asian J Surg 2004;27(1):4–9]
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both smooth muscle and neuropeptide innervation, suggest-
ing the presence of vasoactive substances causing these changes
in hepatic blood flow.4 To date, three isoforms of endothelin
(ET) have been identified (ET-1, ET-2 and ET-3), each com-
posed of 21 amino acids.5 ET-1, a potent vasoconstrictor
peptide, is the principal isoform and was originally isolated
from the cultured media of aortic endothelial cells.6 Due
to a low circulating concentration and a short plasma half-
life (about 1.5 minutes), measurement of plasma ET-1 con-
centrations has proven to be difficult. Big ET-1, the precursor,
is a stable peptide with a plasma half-life of 30 minutes,
making the measurement of plasma big ET-1 concentrations
a sensitive indicator of endothelin system activation.7 We
speculate that ET could be the vasoactive factor involved in
the haemodynamic changes noted in colorectal hepatic
metastases.
This prospective study was performed to determine whether
preoperative plasma big ET-1 concentrations might be useful
as a prognostic factor in patients with colorectal carcinoma.
Patients and methods
To determine the normal range of plasma big ET-1
concentrations, peripheral plasma samples were obtained from
an age–sex-matched group with no history of cancer.
A total of 65 consecutive patients with colorectal cancer
confirmed by biopsy who underwent surgery were included
prospectively in this study from 1998 to 2001. Patients
with co-morbid conditions that are associated with elevated
big ET-1 concentrations, such as hypertension, cardiac
failure, myocardial infarction and rheumatic diseases, were
excluded.
Local ethical approval was obtained prior to the start of
this study. Patients were given an information leaflet about
the study and informed consent was then obtained.
Blood collection
Plasma samples from a peripheral vein were obtained prior to
surgery. Samples were taken in a seated position. All blood
samples were collected in EDTA specimen tubes, placed imme-
diately into an ice bag and centrifuged at 2,000 rpm (Sigma
centrifuge model no. 4k15, Sigma Laboratories, Dorset, UK)
for 10 minutes at 4°C within 15 minutes of blood collection.
The plasma supernatant was drawn off, snap frozen in liquid
nitrogen and stored at –80°C.
An individual who was blinded to the plasma big ET-1
concentrations collected data from pathology reports on the
colorectal cancer specimen and patients’ details independ-
ently for all patients. Previous studies have analysed clinico-
pathological variables such as age (> 70 years), gender, tumour
size, vascular invasion and tumour stage.8,9 However, in this
study, we also assessed plasma big ET-1 concentrations as a
clinical variable prior to surgery. A plasma concentration of
more than 4.2 pg/mL was chosen because this was the upper
limit of big ET-1 concentrations in age–sex-matched controls.
Only variables predicting survival in the univariate analysis
were used in the multivariate analysis.
Assessment of plasma big ET-1 concentrations
Plasma big ET-1 concentrations were measured within
2 months of sample collection using a one-step sandwich
enzyme immunoassay kit (Biomedica, Vienna, Austria) in
accordance with the manufacturer’s protocol. All standards
and patient samples were analysed in duplicate and the mean
value taken.
The kit consisted of purified polyclonal antibody and
monoclonal detection antibody highly specific for big ET-1 (1-
38). Big ET-1 binds to the pre-coated antibody and forms a
sandwich with the detection antibody. Big ET-1 was quanti-
fied using an enzyme-catalyzed colour change detectable on a
standard enzyme-linked immunosorbent assay (ELISA) reader
(Denley scan, R&D Systems, Abingdon, UK). The detection
range for this assay was 0.125–39 pg/mL, and the cross reactiv-
ity with human big ET-1 (22-38), ET-1, ET-2 and ET-3 was less
than 1%. The intra- and inter-assay coefficient variations for
this assay kit were 5% and 8%, respectively. Plasma big ET-1
concentrations were calculated by extrapolation from a stand-
ard curve. A separate standard curve was constructed for each
ELISA batch.
Statistical analysis
Kaplan-Meier survival curves and the log rank test were used
to analyse survival differences. Univariate and multivariate
analyses (Cox’s proportional hazard) of all clinicopathologi-
cal variables were performed using SPSS version 10.1 (SPSS
Inc, Chicago, IL, USA). A p value of less than 0.05 was consid-
ered significant. Only variables shown by univariate analysis
to be associated with survival were entered into the multivariate
analysis.
Results
A total of 69 patients with primary colorectal cancer without
evidence of distant metastasis were included in this study (41
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males and 28 females). The median age was 69 years (range, 42–
92 years). Although all patients had apparently curative resec-
tions for their primary tumour, two patients with locally
advanced tumours underwent palliative resection only and
they were excluded from the study. Overall survival at a mean
of 14 months (range, 2–36 months) from surgery was 72.3%.
Patients who died within 30 days of surgery (n = 2) were also
excluded from the study. Sixty-five patients were therefore
available for analysis.
Plasma big ET-1 concentration and disease status
Of the 65 patients, 26 (40%) had elevated plasma big ET-1
concentrations (> 4.2 pg/mL; Table 1). Of the 31 patients with
Dukes’ A/B colorectal cancer, 14 (45%) had elevated plasma big
ET-1 concentrations. Similarly, of 34 patients with Dukes’ C
cancer, 12 (35%) had elevated plasma big ET-1 concentrations
(Table 2). To assess whether elevated plasma big ET-1 concen-
trations were related to tumour load and vascular invasion,
these variables were compared to big ET-1 concentrations. Of
36 patients with smaller primary tumours (< 5 cm), 22 (61%)
had plasma big ET-1 concentrations of less than 4.2 pg/mL.
Furthermore, only 16 of 40 patients (40%) with evidence of
vascular invasion had elevated plasma big ET-1 concentrations.
Interestingly, 29% of patients with high concentrations of
plasma big ET-1 in the Dukes’ A/B group died (4/14), but only
6% of patients with low concentrations of big ET-1 in this
group died (1/17).
Univariate analysis of survival
Three variables (age, Dukes’ tumour stage and plasma big
ET-1 concentration) had prognostic significance (p < 0.05).
Factors associated with a poorer prognosis were a tumour of
Dukes’ stage C, a plasma big ET-1 concentration of more than
4.2 pg/mL, and age more than 70 years (Figures 1–4). There
was no significant survival difference with respect to gender,
tumour size and presence of vascular invasion on tumour
sections (Table 3).
Multivariate analysis of survival
The Cox regression model identified the same three variables
as having independent prognostic value for overall survival
(Table 4). There was a significant difference in survival among
those more than 70 years old compared to those less than
70 years old (p = 0.02). Survival was significantly better in
patients with Dukes’ A/B cancer than those with Dukes’ C
cancer (p = 0.01). Similarly, preoperative plasma big ET-1
concentrations predicated survival (< vs > 4.2 pg/mL; p = 0.01).
Table 1. Characteristics of clinical and pathological variables
Number of patients
Gender
Male 39
Female 26
Age
< 70 yr 29
> 70 yr 36
Dukes’ staging
A/B 31
C 34
Vascular invasion
Present 40
Absent 25
Tumour size (largest diameter)
< 50 mm 36
> 50 mm 29
Plasma big ET-1
< 4.2 pg/mL 39
> 4.2 pg/mL 26
ET-1 = endothelin-1.
Table 2. Relationship between plasma big endothelin-1 (ET-1)
concentrations and Dukes’ staging
Duke’s stage
A/B, n (%) C, n (%)
Plasma big ET-1
< 4.2 pg/mL 17 (55) 22 (65)
> 4.2 pg/mL 14 (45) 12 (35)
Total 31 (45) 34 (45
Figure 1. Kaplan-Meier survival curves for patients with Dukes’
A/B cancer (solid line) and Dukes’ C cancer (dotted line).
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Figure 2. Kaplan-Meier survival curves for patients with plasma big
endothelin-1 (ET-1) concentrations below 4.2 pg/mL (solid line)
and above 4.2 pg/mL (dotted line).
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Figure 3. Kaplan-Meier survival curves for patients less than 70
years old (solid line) and more than 70 years old (dotted line).
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Figure 4. Kaplan-Meier survival curves for patients with Dukes’
A/B and plasma big endothelin-1 (ET-1) concentrations less than
4.2 pg/mL (solid line), Dukes’ A/B and plasma big ET-1 concentra-
tions more than 4.2 pg/mL (dashed line), Dukes’ C and plasma big
ET-1 concentrations less than 4.2 pg/mL (dotted line), and Dukes’
C and plasma big ET-1 concentrations more than 4.2 pg/mL
(dashed line with centre dots).
0 10 20 30
Time after operation (mo)
No. of patients at risk
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Discussion
In this study, we demonstrated that age, Dukes’ stage and
plasma big ET-1 concentration were significant prognostic
factors both by univariate and multivariate analyses in
patients with colorectal cancer. Overall survival decreased
in patients older than 70 years in this study; other groups
have reported similar results.8,10,11 The significance of age is
frequently reviewed and yet remains controversial. Some groups
have shown similar cancer-related death outcomes in both the
Table 3. Results of the univariate analysis
Hazard Confidence Log-rank
ratio interval test p
Gender
Male 1.00
Female 1.51 0.56–4.03 0.41
Age
< 70 yr 1.00
> 70 yr 4.43 1.27–15.48 0.02
Dukes’ staging
A/B 1.00
C 2.86 1.00–8.67 0.04
Vascular invasion
Absent 1.00
Present 2.43 0.16–1.08
Tumour size
(largest diameter)
< 50 mm 1.00
> 50 mm 2.44 0.91–6.53 0.08
Plasma big ET-1
< 4.2 pg/mL 1.00
> 4.2 pg/mL 3.34 1.25–8.98 0.02
ET-1 = endothelin-1.
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elderly and younger age groups.12 Many have suggested that
the poor prognosis in elderly patients is due to co-existing
disease and poor physiological reserve.11,13 Although patients
with serious illness were excluded from the study to avoid the
confounding effect of raised plasma big ET-1 concentrations
in these conditions, we found that the elderly group did poorly
in terms of survival following surgery for colorectal cancer.
This study reinforces the importance of Dukes’ classifica-
tion in predicting overall outcome after colorectal cancer
surgery. However, this information is known only in the post-
operative period. Dukes reported a crude 5-year survival rate of
82% for patients with Dukes’ A cancer, instead of the 100%
expected for this type of cancer when there is no evidence of
spread beyond the bowel. The reporting of cancer sections
could vary between centres because careful dissection to iden-
tify tumour spread beyond the muscularis mucosa is different
due to technical reasons, and small lymph node metastases
may be missed. In spite of these disadvantages, Dukes’ staging
is still used as a standard method. Moreover, attempts to create
a new staging system have resulted in more confusion than
refinement.
Plasma big ET-1 concentrations are elevated among
colorectal cancer patients with liver metastases in comparison
to colorectal cancer patients without metastases.14 Plasma
ET-1 concentrations increase with increasing size of liver
metastases,15 with no significant difference in concentrations
between patients with primary colorectal cancer without
metastases and a control group. These findings suggest that
ET-1 could be involved in the spread of colorectal cancer to the
liver. Ferrari-Bravo et al investigated 14 consecutive patients
who underwent surgery for gastric cancer.16 Mean plasma
concentrations of ET-1 reduced significantly 50 days
after surgery compared to preoperative concentrations.
Interestingly, the reduction in postoperative ET concentra-
tion was significantly smaller among patients with less ad-
vanced disease than advanced disease. These results indicate
that ET-1 may be secreted by the cancer and, when the tumour
is removed, the ET-1 concentration will fall in less advanced
cancer. Advanced gastric cancer may still have micrometastases
that continue to produce ET-1.
In this study, preoperative plasma big ET-1 concentrations
were an important independent prognostic factor in patients
with colorectal cancer. We speculate that increased plasma ET
concentrations may indicate unidentified micrometastatic
disease, predicting a poor outcome in a proportion of patients
with favourable staging. Of node-negative colorectal cancer
patients, 30% develop recurrent disease, yet these patients do
not routinely receive adjuvant chemotherapy to prevent
recurrence. Our study identified 29% of patients with elevated
ET concentrations and Dukes’ A/B staging who subsequently
died. Measurement of plasma big ET-1 concentrations could
be used to identify patients with node-negative disease who
may benefit from adjuvant therapy. Gender, tumour size and
vascular invasion were not associated with any survival differ-
ence among the cancer patients. Follow-up of these patients
for another 3 years may show the significance of other vari-
ables that were not significant in this study.
In conclusion, preoperative plasma big ET-1 concentra-
tions may be useful in predicting survival in colorectal cancer
patients. Plasma big ET-1 concentrations may be useful in the
selection of high-risk lymph node-negative patients with
colorectal cancer for adjuvant therapy.
Acknowledgement
This preliminary study was funded internally by departmental
funds .
References
1. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortal-
ity in the European Union: cancer registry data and estimates of
national incidence for 1990. Eur J Cancer 1997;33:1075–107.
2. Hemingway DM, Cooke TG, Grime SJ, et al. Changes in hepatic
haemodynamics and hepatic perfusion index during the growth and
development of hypovascular HSN sarcoma in rats. Br J Surg 1991;
78:326–30.
3. Hemingway DM, Cooke TG, Warren H, et al. Dynamic hepatic
scintigraphy in colorectal cancer. Nucl Med Commun 1995;16:867–9.
4. Ashraf S, Crowe R, Loizidou MC, et al. The absence of autonomic
perivascular nerves in human colorectal liver metastases. Br J Cancer
Table 4. Results of the multivariate analysis (Cox proportional
hazard)
Hazard Confidence
ratio interval
p
Age
< 70 yr 1.00
> 70 yr 4.42 1.25–15.57 0.02
Dukes’ staging
A/B 1.00
C 3.79 1.30–11.03 0.01
Plasma big ET-1
< 4.2 pg/mL 1.00
> 4.2 pg/mL 3.57 1.29–9.88 0.01
ET-1 = endothelin-1.
■ PROGNOSTIC SIGNIFICANCE OF ENDOTHELIN-1 IN CRC ■
ASIAN JOURNAL OF SURGERY  VOL 27 • NO 1 • JANUARY 2004 9
070/2001
1996;73:349–59.
5. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin
family: three structurally and pharmacologically distinct isopeptides
predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:
2863–7.
6. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasocon-
strictor peptide produced by vascular endothelial cells. Nature 1988;
332:411–5.
7. Hemsen A, Ahlborg G, Ottosson-Seeberger A, Lundberg JM. Me-
tabolism of big endothelin-1 (1-38) and (22-38) in the human
circulation in relation to production of endothelin-1 (1-21). Regul
Pept 1995;55:287–97.
8. Wolters U, Stutzer H, Keller HW, et al. Colorectal cancer—a multi-
variate analysis of prognostic factors. Eur J Surg Oncol 1996;22:592–7.
9. Deans GT, Patterson CC, Parks TG, et al. Colorectal carcinoma:
importance of clinical and pathological factors in survival. Ann R
Coll Surg Engl 1994;76:59–64.
10. Fielding LP, Phillips RK, Hittinger R. Factors influencing mortality
after curative resection for large bowel cancer in elderly patients.
Lancet 1989;i:595–7.
11. Irvin TT. Prognosis of colorectal cancer in the elderly. Br J Surg
1988;75:419–21.
12. Umpleby HC, Williamson RC. Large bowel cancer in the young.
Ann Acad Med Singapore 1987;16:456–61.
13. Fielding LP, Phillips RK, Fry JS, Hittinger R. Prediction of outcome
after curative resection for large bowel cancer. Lancet 1986;ii:904–7.
14. Simpson RA, Dickinson T, Porter KE, et al. Raised levels of plasma
big endothelin 1 in patients with colorectal cancer. Br J Surg 2000;
87:1409–13.
15. Shankar A, Loizidou M, Aliev G, et al. Raised endothelin 1 levels in
patients with colorectal liver metastases. Br J Surg 1998;85:502–6.
16. Ferrari-Bravo A, Franciosi C, Lissoni P, et al. Effects of oncological
surgery on endothelin-1 secretion in patients with operable gastric
cancer. Int J Biol Markers 2000;15:56–7.
